{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:39:13Z","timestamp":1776987553231,"version":"3.51.4"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/gme.0b013e3181906fa3","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T19:53:57Z","timestamp":1242935637000},"page":"609-615","source":"Crossref","is-referenced-by-count":38,"title":["Designing the ideal selective estrogen receptor modulator-an achievable goal?"],"prefix":"10.1097","volume":"16","author":[{"given":"Hugh S.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-32-20210227","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen receptor modulators - mechanisms of action and application to clinical practice.","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-32-20210227","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1091\/mbc.e03-06-0360","article-title":"Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors and .","volume":"15","author":"Kian","year":"2004","journal-title":"Mol Biol Cell"},{"key":"R3-32-20210227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/0929867033368501","article-title":"Advances in the science of estrogen receptor modulation.","volume":"10","author":"Meegan","year":"2003","journal-title":"Curr Med Chem"},{"key":"R4-32-20210227","first-page":"437","article-title":"Recent advances in estrogen receptor modulators.","volume":"8","author":"Henke","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R5-32-20210227","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/13543776.16.5.559","article-title":"Estrogen receptor modulator review.","volume":"16","author":"Ullrich","year":"2006","journal-title":"Exp Opin Ther Patents"},{"key":"R6-32-20210227","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","article-title":"Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.","volume":"591","author":"Lewis","year":"2005","journal-title":"Mutat Res"},{"key":"R7-32-20210227","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00129785-200404010-00003","article-title":"Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action.","volume":"4","author":"Barkhem","year":"2004","journal-title":"Am J Pharmacogenomics"},{"key":"R8-32-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1258\/175404507780456791","article-title":"The future of the new selective estrogen receptor modulators.","volume":"13","author":"Palacios","year":"2007","journal-title":"Menopause Int"},{"key":"R9-32-20210227","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators.","volume":"25","author":"Smith","year":"2004","journal-title":"Endocr Rev"},{"key":"R10-32-20210227","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer.","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"},{"key":"R11-32-20210227","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/jnci\/93.19.1449","article-title":"Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.","volume":"93","author":"Jordan","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R12-32-20210227","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R13-32-20210227","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1043-2760(99)00177-0","article-title":"The molecular pharmacology of SERMs.","volume":"10","author":"McDonnell","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"R14-32-20210227","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment.","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R15-32-20210227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0020-7292(96)90115-0","article-title":"ACOG committee opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice.","volume":"53","year":"1996","journal-title":"Int J Gynaecol Obstet"},{"key":"R16-32-20210227","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/sonc.2001.23492","article-title":"Tamoxifen to raloxifene and beyond.","volume":"28","author":"O'Regan","year":"2001","journal-title":"Semin Oncol"},{"key":"R17-32-20210227","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"R18-32-20210227","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1196\/annals.1365.034","article-title":"The cardiovascular effects of selective estrogen receptor modulators.","volume":"1092","author":"Christodoulakos","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R19-32-20210227","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","article-title":"Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.","volume":"85","author":"Rutqvist","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R20-32-20210227","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"R21-32-20210227","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R22-32-20210227","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","article-title":"Symptoms associated with tamoxifen treatment in postmenopausal women.","volume":"151","author":"Love","year":"1991","journal-title":"Arch Intern Med"},{"key":"R23-32-20210227","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(05)72466-1","article-title":"Occurrence of stroke with tamoxifen in NSABP B-24.","volume":"355","author":"Dignam","year":"2000","journal-title":"Lancet"},{"key":"R24-32-20210227","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"R25-32-20210227","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"R26-32-20210227","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"R27-32-20210227","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-32-20210227","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"R29-32-20210227","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R30-32-20210227","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"R31-32-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R32-32-20210227","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"R33-32-20210227","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1068-607X(98)00066-3","article-title":"Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women.","volume":"5","author":"Glusman","year":"1998","journal-title":"Prim Care Update Ob Gyns"},{"key":"R34-32-20210227","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene.","volume":"93","author":"Davies","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R35-32-20210227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","article-title":"Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.","volume":"34","author":"Cohen","year":"2000","journal-title":"Maturitas"},{"key":"R36-32-20210227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7863\/jum.1999.18.7.503","article-title":"Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.","volume":"18","author":"Fleischer","year":"1999","journal-title":"J Ultrasound Med"},{"key":"R37-32-20210227","first-page":"21","article-title":"","volume":"2431","year":"1999","journal-title":"SCRIP"},{"key":"R38-32-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-5122(02)00342-0","article-title":"Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal.","volume":"44","author":"Warming","year":"2003","journal-title":"Maturitas"},{"key":"R39-32-20210227","first-page":"18","article-title":"","volume":"2374","year":"1998","journal-title":"SCRIP"},{"key":"R40-32-20210227","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.","volume":"949","author":"Komm","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"suppl 1","key":"R41-32-20210227","first-page":"S413","article-title":"TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion Abstract SU437.","volume":"16","author":"Ronkin","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"suppl 7","key":"R42-32-20210227","first-page":"S14","article-title":"Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain Abstract OC39.","volume":"14","author":"Boudes","year":"2003","journal-title":"Osteoporos Int"},{"key":"R43-32-20210227","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R44-32-20210227","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study published erratum appears in J Bone Miner Res 2008;23:972.","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R45-32-20210227","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial.","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"suppl 1","key":"R46-32-20210227","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.fertnstert.2007.07.824","article-title":"Endometrial and ovarian safety of bazedoxifene (BZA) in the prevention of postmenopausal osteoporosis Abstract P-407.","volume":"88","author":"Pinkerton","year":"2007","journal-title":"Fertil Steril"},{"key":"R47-32-20210227","first-page":"1091","article-title":"Endometrial safety of bazedoxifene, a new selective estrogen receptor modulator (SERM), in the treatment of postmenopausal (PM) osteoporosis Abstract P-14.","volume":"14","author":"Archer","year":"2007","journal-title":"Menopause"},{"key":"R48-32-20210227","first-page":"S10","article-title":"Tissue selective estrogen complex: a new paradigm for menopausal therapy.","volume":"16","author":"Pickar","year":"2008","journal-title":"Menopausal Med"},{"key":"R49-32-20210227","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/13543784.16.10.1663","article-title":"Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.","volume":"16","author":"Lewiecki","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R50-32-20210227","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"R51-32-20210227","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00042192-200512020-00020","article-title":"Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA).","volume":"12","author":"Bachmann","year":"2005","journal-title":"Menopause"},{"key":"R52-32-20210227","first-page":"670","article-title":"Clinical signs of vaginal atrophy are improved by the SERM, lasofoxifene Abstract P-68.","volume":"11","author":"Gass","year":"2004","journal-title":"Menopause"},{"key":"R53-32-20210227","first-page":"669","article-title":"Lasofoxifene improves symptoms associated with vaginal atrophy Abstract P-63.","volume":"11","author":"Bachmann","year":"2004","journal-title":"Menopause"},{"key":"R57-32-20210227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"R58-32-20210227","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"R59-32-20210227","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"R60-32-20210227","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women.","volume":"24","author":"Komi","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"R61-32-20210227","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women.","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"R62-32-20210227","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/13543784.15.3.317","article-title":"Arzoxifene: the development and clinical outcome of an ideal SERM.","volume":"15","author":"Munster","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R63-32-20210227","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1158\/1078-0432.CCR-04-0171","article-title":"Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.","volume":"10","author":"Fabian","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R64-32-20210227","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2001.19.7.2002","article-title":"Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.","volume":"19","author":"Munster","year":"2001","journal-title":"J Clin Oncol"},{"key":"R65-32-20210227","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/annonc\/mdg368","article-title":"Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.","volume":"14","author":"Baselga","year":"2003","journal-title":"Ann Oncol"},{"key":"R66-32-20210227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-8258(03)00203-8","article-title":"A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.","volume":"90","author":"McMeekin","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R67-32-20210227","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2003.06.108","article-title":"Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.","volume":"21","author":"Buzdar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R68-32-20210227","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","article-title":"Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.","volume":"25","author":"Deshmane","year":"2007","journal-title":"J Clin Oncol"},{"key":"R70-32-20210227","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjp.0706960","article-title":"Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).","volume":"150","author":"Ning","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R71-32-20210227","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1021\/jm0509795","article-title":"A selective estrogen receptor modulator for the treatment of hot flushes.","volume":"49","author":"Wallace","year":"2006","journal-title":"J Med Chem"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042192-200916030-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:31:25Z","timestamp":1618277485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-200916030-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181906fa3","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}